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Physiological concentrations of albumin favor
drug binding†
D. Tatlidil,a M. Ucuncub and Y. Akdogan*a
The ability to track drug binding and release makes electron paramagnetic resonance (EPR) spectroscopy
well suited for drug delivery studies. Using the continuous wave (cw) EPR technique to extract information
about the dynamics of the spin labeled drugs we can simultaneously determine the bound and unbound
drugs. Here, spin labeled salicylic acid (SLSA) binding to and release from bovine serum albumin (BSA) is
investigated, as a model for drug–transport protein interaction. We studied SLSA–BSA binding in a wide
concentration range and found that the stoichiometry of the drug–protein increases significantly when
the physiological range of BSA concentration is reached. Our EPR results explicitly reveal that up to
B7 SLSA can bind to one albumin at the physiological concentration, whereas at lower BSA concentra-
tions (o0.125 mM) the SLSA–BSA stoichiometry is maximum 2. Moreover, we studied drug release and
showed that the ratio of bound to unbound SLSA concentrations remains relatively stable during dialysis.
This indicates that the binding equilibrium of SLSA is not altered through the process of dialysis. This study
demonstrates that cw EPR spectroscopy in combination with spin labeled drugs is an effective technique
for binding and release studies and stoichiometric analysis of drug–protein interactions.
Introduction
The extent of drug–transport protein binding is important to
determine the drug dose. Drugs can travel in the system either
as free floating molecules or as protein bound molecules in a
reversible manner. Mostly, the unbound drug concentration,
rather than the protein bound concentration, is used to deter-
mine the effect of a drug.1,2 On the other hand, protein binding
prevents drugs to be metabolized completely or to reach high
toxic levels. The bound fraction is released slowly to maintain
equilibrium. Binding and release of drugs are altered in a range
of physical and chemical conditions.3,4 Therefore, understanding
the factors that affect the drug binding to and release from proteins
in the plasma or tissue is very important.
Several spectroscopic techniques have been used in order to
study the interaction between drugs and proteins, including
fluorescence,5 UV-vis,6 FTIR6 and NMR7 spectroscopies. Some
of these techniques have been used only to observe the changes
in proteins instead of drugs in the protein-drug complexes. For
example, the intrinsic fluorescence of bovine serum albumin
(BSA) was monitored by fluorescence emission spectroscopy in
the presence of aspirin.5 Since aspirin binding or interaction
quenches the fluorescence of albumin, fluorescence spectro-
scopy is used as an indirect method to observe the binding of
aspirin to albumin. Similarly, interactions of vitamin C and
aspirin with BSA were studied by FTIR to examine the variations
in the stability and conformation of BSA.6 In the same study,
UV-vis spectroscopy was used to calculate the binding constants
of the drugs by considering the absorbance values of drugs,
BSA and drug–BSA complexes.6 Since absorption wavelengths
of free aspirin, free BSA and the aspirin–BSA complex are very
similar, it is difficult to distinguish the bound/unbound ratio of
aspirin in the final aspirin–BSA complex using UV-vis spectro-
scopy. Differently, in the NMR spectroscopy, changes in the
chemical shifts and relaxation rates of a particular part of drugs
can be the proof of a drug–protein complex formation.7 The
part of the drug which strongly binds to protein has longer
correlation time than the other parts of the drug. Therefore,
NMR allows direct monitoring of the site of interest in the drug.
However, such studies cannot simultaneously display the signa-
tures of the bound and unbound drugmolecules, especially within
the physiological range of albumin.
Electron paramagnetic resonance (EPR) spectroscopy in com-
bination with spin labeling is a powerful method for studying
the interaction between small drugs and biomacromolecules.9,10
Since most of the drugs are diamagnetic and contain no para-
magnetic centres, exogenous stable free radicals called spin
labels are used as reporters. Tempo (2,2,6,6-tetramethylpiperidine-
1-oxyl) based nitroxide radicals, the most commonly employed
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spin label, can be attached to a proper functional group on the
drug (Fig. 1). Spin labeled drugs have been synthesized and
used to study the drug mechanisms at a molecular level for a
long time.11–13 Besides their reporter properties, nitroxides are
also used in anti-oxidant therapies for several diseases because
they can effectively scavenge the reactive oxygen species and
therefore improve cell viability.14,15
Here, we use continuous wave (cw) EPR spectroscopy as an
alternative technique to study the interaction between drugs
and proteins. One major advantage of cw EPR spectroscopy is
the ability to observe the unbound drug and the bound drug
simultaneously, due to its sensitivity to the rotational dynamics
of the radicals.11–13 Bound spin labeled molecules (immobilized)
have characteristic broad signals stemming from restricted
rotational motion, and unbound spin labeled molecules
(mobilized) have sharp three-line signals coming from freely
tumbling motion.16–18
Salicylic acid (SA), which is a non-steroidal anti-inflammatory
drug, and serum albumin, which is the most abundant plasma
protein, were used as a model drug and transporter protein,
respectively. SA contains two functional groups, a carboxylic acid
(–COOH) group and a hydroxyl (–OH) group (Fig. 1). In order
to preserve these functional groups, spin label is covalently
attached to the phenyl group of SA, and so that spin labeled
salicylic acid (SLSA) is synthesized (Fig. 1 and Fig. S1, ESI†).
Human serum albumin (HSA) with three a-helical domains
(I–III) serves as a carrier of many drugs from the bloodstream to
target cells.19 The domains II and III contain two principal
ligand binding sites, known as Sudlow’s sites I and II, respec-
tively.20 Furthermore, several other binding sites were also observed
including seven long fatty acid binding sites.21,22 Bovine serum
albumin (BSA) has been widely used in experiments due to its
structural homology to HSA (76% of amino acid sequence
homology) and its lower cost (Fig. 1).5–7
Here, we specifically aim at studying in vitro SLSA binding
and release profiles of BSA as well as the SLSA capacity of BSA at
different albumin concentrations. Dynamics of drugs changes
enormously upon protein binding so we can monitor the bound
and unbound spin labeled drug in the presence of albumin
simultaneously by EPR spectroscopy.
Experimental section
Reagents and instruments
Bovine serum albumin (fatty acid free), 4-amino salicylic acid,
Tempo-4-amino, hydrochloric acid (37%, 12.2 M), dichloro-
methane (99.8%), trimethylamine (99.5%), ethyl acetate (99.5%),
methanol (99.8%) were purchased from Sigma-Aldrich. Thio-
phosgene (99%) was purchased from Merck. All reagents were
used without further purification. All solvents were of analytical-
reagent grade. Doubly distilled water was used throughout the
experiments.
The samples were measured on a Varian Cary Eclipse Fluores-
cence spectrophotometer equipped with 1.0 cm path length quartz
cuvettes and a CMS 8400 (Adani) benchtop X-band EPR spectro-
meter with a TE102 resonator cavity.
Synthesis of spin labeled salicylic acid (SLSA)
4-Amino salicylic acid (0.01 mol) was dissolved in 32 mL water
and then acidified with 3.4 mL HCl (12.2 M) in a 100 mL
reaction tube with a stopcock. Thereafter, thiophosgene (0.044mol)
was introduced. After stirring for 1 hour at 0 1C (in an ice bath), the
solution was stirred for 2.5 hours at 25 1C. The solution was filtered
and dried under vacuum. 4-Isothiocyanate salicylic acid was
isolated as a white powder. The yield of the experiment was
50% (Fig. S1, ESI†).
Tempo-4-amino (0.625 mmol) and 4-isothiocyanate salicylic
acid (0.46 mmol) were dissolved in 20 mL DCM in a 50 mL
flask. A few drops of triethylamine were added and stirred
overnight at 25 1C. Tempo attached salicylic acid (spin labeled
salicylic acid, SLSA) was purified with column chromatography
(ethyl acetate :methanol, 15 : 1, 13 : 1, 12 : 1 and 10 : 1). The yield
of the experiment was 46% (Fig. S1, ESI†).23
Binding of SLSA to BSA
Aqueous solutions of BSA at different concentrations were
prepared in 0.1 M phosphate buffer (pH 7.4) in 10 mL vials.
The SLSA stock solution (1 M) was prepared in DMSO in a 0.2 mL
pcr tube. The desired ratio of SLSA to BSA was obtained with the
addition of an appropriate amount of SLSA solution to the protein
solution with constant stirring to ensure the formation of a
homogeneous solution. In the final solution, the DMSO concen-
tration was kept below 1% (v/v). The solution was allowed to
equilibrate at 37 1C for 20 min for the fluorescence and EPR
measurements.
Release of SLSA from BSA
SLSA release from BSA was studied in phosphate buffer (0.1 M,
pH 7.4) at 25 1C and 37 1C. 3 mL, 0.5 mM SLSA in BSA solution
(SLSA/BSA, 1 : 1) was placed in a D-tube dialyzer (Merck, MWCO
6–8 kDa), and then the solution was placed in a beaker contain-
ing 1000 mL release phosphate buffer (0.1 M, pH 7.4) under
stirring at 1500 rpm. At prefixed times a 7 mL sample was
removed from the D-tube dialyzer and measured by EPR
spectroscopy to determine the amount of SLSA diffused as well
as the ratio of bound/unbound SLSA in the albumin solution.
Fig. 1 (A) Chemical structures of 4-amino salicylic acid (SA), Tempo based
nitroxide radicals (R: –OH, –NH2, –COOH, –O, –NCS, etc.) and spin
labeled salicylic acid (SLSA). (B) Crystal structure (pdb-ID: 3v03) of bovine
serum albumin (BSA).8
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Fluorescence measurements
Fluorescence measurements were carried out using a Varian
Cary Eclipse Fluorescence spectrophotometer equipped with
1.0 cm path length quartz cuvettes. Upon excitation at 278 nm,
the emission spectra were collected in the range of 300–550 nm.
The slit width was 5 nm for both excitation and emission. 10 mL
salicylic acid (SA) or spin labeled salicylic acid (SLSA) (6 
102 mM) was added to 3.0 mL BSA (2 104 mM) in phosphate
buffer. For the bare BSA measurement, 10 mL buffered solution
was also added to 3.0 mL BSA. Similarly, bare SA and SLSA were
measured in the absence of BSA.
EPR measurements
A CMS 8400 (Adani) benchtop spectrometer provided with a TE102
resonator cavity was used for all X-band EPR measurements at a
microwave frequency ofB9.4 GHz. Experiments were performed
at 25 1C using a modulation amplitude of 0.1 mT. Measurements
were performed in quartz capillary sample tubes.
The shown EPR spectra were normalized to the intensity of
the high field line of the unbound SLSA. In the EPR spectrum,
the high field line of the unbound SLSA is the least affected
signal by the presence of bound SLSA’s signals. All spectra
were simulated with the Matlab-based Easyspin 4.5.5 software
package.24
Results and discussion
We have synthesized the nitroxide derivative of the SA to study
the binding of the SA drug to BSA protein. In the synthesis of
SLSA, we used 4-amino SA to preserve the functional groups of
SA (–COOH and –OH) (Fig. S1, ESI†). First, 4-amino SA was
transformed into 4-isothiocyanate SA. In the following step, the
nitroxide based Tempo radical was attached to the isothiocyanate
group of SA. Tempo radicals have excellent stability at both physio-
logical temperature and pH, and are commercially available with
several functional groups at the 4-position (Fig. 1).
A crystallographic structural study of the HSA–SA complex
showed that the carboxylate group of SA forms hydrogen bonds
with surrounding amino acids in site I.25 Moreover, the coordi-
nation of hydroxyl and phenyl groups of SA with hydrophobic
residues of HSA was also reported.25 Here, spin labeling of the
SA increases the hydrophobicity of the SA while keeping the
carboxylate and hydroxyl groups still active. Considering these
possible interactions between SA and BSA, it is not surprising
that the more hydrophobic nitroxide derivative of the SA (SLSA)
could bind to BSA.
Fluorescence spectroscopy studies on the binding of SA and
SLSA to BSA
In order to compare the binding ability of SA and SLSA to BSA,
fluorescence emission spectra of BSA were recorded in the absence
and presence of SA and SLSA (Fig. 2).
Intrinsic tryptophan fluorescences (Trp-212 and Trp-134)
dominate the BSA fluorescence spectrum with a maximum at
350 nm. Moreover, SA has a characteristic fluorescence emission
spectrum with a maximum at around 410 nm. However, fluores-
cence emission intensity of SLSA is about 11 times weaker than
that of SA because spin labeling of SA quenched the fluorescent
signal of the SA due to the interaction between the nitroxide
radical and the fluorophore (Fig. 2, dashed lines).
In general, the fluorescence intensity of BSA decreases when
other molecules bind to BSA due to the distortion of the micro-
environment around the tryptophan residues of BSA.5,26 Ni
et al. showed that the addition of SA to BSA decreases the fluores-
cence intensity of BSA at 350 nm, and a second peak appears
at B410 nm.5 Fig. 2 shows that the fluorescence intensity of
BSA (2  104 mM) decreases upon addition of SA and SLSA
at a drug/BSA ratio of 1. However, the second peak at
410 nm appears only upon addition of SA. Unambiguously,
the decreasing ratios in fluorescence intensity of BSA are very
similar after SA and SLSA contributions. This observation
suggested that BSA binding abilities of SA and SLSA are very
comparable.
Furthermore, Fig. S2 (ESI†) showed the fluorescence emis-
sion spectra of BSA (1.5  107 M) in the presence of SA with
different concentrations (0–4.3  107 M) at 303 K. The
fluorescence band intensity of BSA decreases (quenches) upon
addition of SA. At the same time, a second peak corresponding
to SA appears gradually.
The quenching is generally characterized by the Stern–Volmer
equation.27
F0/F = 1 + KSV[Q] (1)
where F0 and F are the fluorescence intensities of the BSA
before and after the addition of the SA (quencher), respectively.
[Q] is the concentration of the quencher (SA). KSV is the dynamic
quenching constant. The KSV value of the SA–BSA complex was
found to be 5.4  105 M within the range of 0–2  107 M SA
concentrations. The quenching behavior of BSA in the presence
of SA slowed down above the 2  107 M SA concentration (the
ratio of [SA] : [BSA] is 1.5) and the quenching ceased after 3.2 
107 M SA concentration which is the limit of detection (the
ratio of [SA] : [BSA] is 2.4) (Fig. S2, ESI†).
Fig. 2 Fluorescence emission spectra of BSA (black) in the presence of SA
(red) and SLSA (blue). The concentration of BSA is 2  107 M in the 0.1 M
phosphate buffer at a drug/BSA ratio of 1. The dashed lines belong to the
fluorescence emission of SA (red) and SLSA (blue) in the buffer solutions
without BSA.
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EPR spectroscopy studies on the binding of SLSA to BSA
In order to study SLSA–BSA binding in detail, first we characterized
the EPR spectrum of SLSA. X-band cw EPR spectra of 0.6 mM SLSA
and Tempo-4-amino in 0.1 M phosphate buffer at 25 1C are
presented in Fig. S3 (ESI†). The usual splitting in three hyperfine
lines comes from the nitrogen nucleus with nuclear spin I = 1 of the
nitroxide group. The EPR parameters of SLSA and Tempo-
4-amino (isotropic g-values (giso), isotropic hyperfine coupling
constants (Aiso) and rotational correlation times (tR)) were derived
from their spectral simulations. Both have similar g-values and
hyperfine values (giso: 2.00554 vs. 2.00552 and Aiso: 1.70 mT vs.
1.68 mT, for SLSA vs. Tempo-4-amino, respectively).
The line shape of an EPR spectrum contains information
about the rotational dynamics of a paramagnetic centre. For both
samples, the low-field and central lines of spectra are almost
equal, but the high field line is less intense for the SLSA. This
indicates the slower rotational motion of SLSA (tR = 0.07) com-
pared to the rotational motion of Tempo-4-amino (tR = 0.02 ns)
(Fig. S3, ESI†). This suggests that binding of SA to Tempo-4-amino
restricts the motion of the radical centre.
Next, we studied SLSA binding to BSA using cw EPR spectro-
scopy (Fig. 3 and 4). In solution, the nitroxide line shape of the
cw EPR spectrum of the spin labeled drug is strongly influenced
by the protein binding. Rotational freedom of the radical center
on the molecule significantly decreases upon macromolecule
binding so that the rotational correlation time increases from the
ps to ms range as a result of the immobilization strength.28 In a
typical room temperature EPR spectrum, the unbound (mobilized)
spin labeled drug possesses sharp three-line signals, signatures of
freely tumbling motion. In contrast, the protein bound (immobi-
lized) spin labeled drug gives signals with broad outer hyperfine
features stemming from restricted rotational motion (Fig. 3).
Therefore, the EPR spectroscopy technique allows simultaneous
detection of bound and unbound spin labeled drug molecules
from their corresponding signals.
Moreover, the ratio of bound to unbound spin labeled drugs,
and the number of bound SLSAmolecules per albumin molecule
can be calculated from the areas under the EPR signals (obtained
by double integrations of EPR spectra, Fig. 4):
Bound½SLSA=½BSA ¼ BoundArea
BoundAreaþUnboundArea
½SLSA
½BSA
(2)
Fig. 3 shows the cw EPR spectrum of 0.6 mM SLSA in the BSA
solution at a SLSA/BSA ratio of 1 with the corresponding
simulation. The simulation of the spectrum was obtained by
the addition of the simulated three line spectrum (unbound
SLSA, tR = 0.07 ns) and simulated broad signals (bound SLSA,
tR = 10 ns). Double integrations of the simulated EPR spectra
of unbound and bound SLSA revealed that B80% of SLSA is
bound to albumin (Fig. 4). As a control experiment, a mixture of
Tempo-4-amino and BSA solution was measured and only three
sharp signals coming from free Tempo-4-amino radicals were
obtained (Fig. S4, ESI†). This indicates that Tempo-4-amino
does not bind to BSA by itself.
Concentration effects on the protein binding
In solution, the extent of drug–protein conjugation increases
when the concentrations of drug and protein increase accord-
ing to the collision theory.29 Fig. 5A shows the cw EPR spectrum
of a concentrated drug–protein solution with 3.0 mM SLSA in
3.0mM BSA solution (1 : 1) (red line). Most of the SLSA are
bound to BSA with a fraction of bound SLSA as 0.95 (Fig. 5B).
When the SLSA–BSA solution is gradually diluted with buffer
while keeping the SLSA/BSA ratio at unity, the fraction of bound
SLSA decreases from 0.95 to 0.50 at 3.0 mM and 0.1 mM BSA,
respectively. This suggests that dilution causes the release of
SLSA from BSA.
Usually, drug binding is a reversible process in which drugs
bind to the albumin with weak chemical bonds, such as
Fig. 3 (1) Cw EPR spectrum of 0.6 mM SLSA in BSA solution (1 : 1) (black)
and its simulation (red). The simulation of the spectrum was obtained by
the addition of simulated unbound SLSA (2) and simulated bound SLSA (3).
Fig. 4 (A) Superposition of simulations of unbound (black) and bound
(red) fractions of the EPR spectrum belongs to 0.6 mM SLSA in BSA solution
(1 : 1). Single integrations (B) and double integrations (C) of EPR spectra in (A).
Double integration is performed to determine the proportion of the bound
and unbound SLSA to the total.
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hydrogen bonds or van der Waals forces.25,30 We have also an
equilibrium between bound and unbound SLSA in the BSA solution.
During the process of diluting the system to lower concentrations,
the collision probability of unbound SLSA and BSA decreases
which reduces the formation of SLSA–BSA conjugation. In order
to maintain the equilibrium between bound and unbound drugs,
BSA releases more SLSA. Thus, the fraction of unbound SLSA
increases and the fraction of bound SLSA decreases regularly.
When we plotted the fraction of bound SLSA in 1 : 1 SLSA : BSA
solutions of varying BSA concentrations (0.1 mM–3.0 mM) we
obtained a saturation curve. The bound fraction is saturated just
above the physiological concentrations of albumin (0.5–0.7 mM).
However, below the physiological concentrations of albumin the
fraction of bound SLSA decreases promptly.
The experimental results show that SLSA can bind to BSA
with a very high efficiency at the physiological concentrations of
BSA. But, below the physiological concentrations, BSA loses its
affinity for SLSA dramatically.
We measured the EPR spectra of 2 mM, 0.8 mM and 0.4 mM
of SLSA in BSA solution at a SLSA/BSA ratio of 1 within a period
of time after preparation of the samples from 1 minute to
30minutes (Fig. S5, ESI†). Since tuning the EPR cavity after sample
insertion and EPR measuring collectively take some time, we
cannot collect the data immediately (0 min).
Fig. S5 (ESI†) shows that EPR spectra of different concentra-
tions of SLSA/BSA (1 : 1) assemblies do not change with time.
The bound to free drug ratio is constant within 30 min. Usually,
drug–protein binding interaction is a kinetically rapid rever-
sible interaction. Therefore, the quick drug association and
dissociation rates in ranges of milliseconds and seconds could
not be calculated by the EPR technique.
Binding stoichiometry of SLSA to BSA
Simulations of EPR spectra of both bound and unbound SLSA
were used to obtain a maximum number of bound SLSA to BSA,
at physiological albumin concentration. For this purpose, SLSA
was added to 0.5 mM BSA solution to generate a series of
samples with different SLSA concentrations from 0.5 to 9.5 mM,
and recorded using EPR spectroscopy.
In the normalized EPR spectra, the intensity of bound SLSA
signals decreases with increasing SLSA concentration (Fig. 6A).
After simulations of each spectrum, the fractions of bound SLSA
were found to be 0.8 and 0.4 in the presence of 0.5mM and 9.5mM
SLSA, respectively (Fig. S6, ESI†).
Although, increasing the concentration of SLSA decreases
the bound fraction of SLSA (Fig. S6, ESI†), the number of bound
SLSA per BSA increases (Fig. 6B). Nonetheless, a deviation from
the straight line coming from the ratio of total SLSA to BSA
concentrations is observed by increasing the concentration of
SLSA. Eventually, SLSA forms a saturated complex with BSA at a
Fig. 5 (A) Cw EPR spectrum of SLSA in BSA solution at a SLSA/BSA ratio of
1. The concentrations of SLSA and BSA from top to bottom are 3.0, 2.5, 2.0,
1.5, 1.0, 0.5 and 0.25 mM, and the free 0.6 mM SLSA in buffer without BSA
(gray color). The EPR spectra are normalized to the intensity of the high
field line of the unbound SLSA. (B) Fraction of bound SLSA obtained from
simulated spectra of 3.0, 2.75, 2.5, 2.0, 1.5, 1.0, 0.85, 0.7, 0.6, 0.5, 0.4, 0.3,
0.25, 0.18 and 0.10 mM SLSA in BSA solutions at a SLSA/BSA ratio of 1.
The circle shows the concentrations of BSA in the physiological range
(0.5–0.7 mM BSA).
Fig. 6 (A) Cw EPR spectra of SLSA in a constant 0.5 mM BSA solution at
different SLSA/BSA ratios. The concentrations of SLSA are 0.5, 1.25, 2.5,
3.75, 5.0, 6.5, 8.0 and 9.5 mM (from top to bottom). 0.5 mM free SLSA in
buffer solution is shown by grey color. The EPR spectra are normalized to
the intensity of the high field line of the unbound SLSA. (B) Ratio of total
SLSA concentration to BSA concentration is shown by black line, and the
ratio of bound SLSA to BSA concentration is shown by red line. Bound SLSA
concentrations are obtained from simulations of EPR spectra from (A).
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molar ratio ofB7 : 1 (SLSA : BSA) (Fig. 6B). This indicates that at
physiological concentration (0.5–0.7 mM) BSA possesses about
7 binding sites for SLSA (eqn 2).
In another experiment, the concentration of BSA was changed
while the concentration of SLSA was kept constant at 0.6 mM.
EPR spectra of 0.6 mM SLSA in different concentrations of BSA
solutions between 3.0–0.3 mM (Fig. 7A) and 0.24–0.02 mM
(Fig. 7B) show that the bound fraction of SLSA decreases from
0.96 (at 3.0 mM BSA) to 0.08 (at 0.02 mM BSA) (Fig. S7, ESI†).
The ratio of bound SLSA/BSA reaches a plateau when the
BSA concentration is as low as 0. 125 mM. Therefore, at lower
BSA concentrations (o0.125 mM) compared to the physiological
range, the maximum binding ratio was found to beB2 : 1 for the
SLSA : BSA interaction (Fig. 7C).
If we compare the bound fractions of SLSA in two BSA
systems (in a physiological range and in a diluted system) at
the samemolar ratio of 19 : 1 (SLSA : BSA), the bound fractions are
0.40 and 0.12 for the SLSA in 0.5 mM BSA and in 0.03 mM BSA,
respectively. Therefore, in the physiological range maximum
B7 SLSA molecules bind per BSA, and in a diluted BSA system
maximum B2 SLSA molecules bind per BSA even at a higher
[SLSA]/[BSA] molar ratio of 30 : 1. Binding stoichiometries of
small drugs to albumin obtained by fluorescence spectroscopy
are also in line with our EPR results. Ni et al. reported the
binding ratios of aspirin–BSA and ibuprofen–BSA as 3 : 1 and
2 : 1, respectively.5 Also, they studied the binding stoichiometry
of SA to BSA and showed that SA primarily binds to site I and may
have two additional low affinity binding sites in site I and II.31
One should be careful when comparing the results of EPR and
fluorescence experiments. Since the fluorescence measurements
were done in the presence of around 0.0002 mM BSA, we can
compare those results with our EPR results obtained from the
diluted BSA system (0.02 mM) not the physiological range
(0.5–0.7 mM).
We have schematically summarized our EPR results in Fig. 8.
A combination of SLSA–BSA dilution experiments (Fig. 5) and
stoichiometry analyses (Fig. 6 and 7) shows that albumin can
bind to maximum 7 SLSA at the physiological range. However,
albumin loses its affinity for SLSA when the concentration of
albumin decreases.
SLSA release study from BSA
The SLSA release profile of BSA was also investigated at two
temperatures 25 1C and 37 1C. 0.5 mM SLSA/BSA (1 : 1) solution
placed in a D-tube dialyzer was measured by EPR spectroscopy
as a function of time (Fig. 9). At time zero the fraction of bound
SLSA is about 0.8. Therefore, two types of SLSA (bound and
unbound) are present in the dialyzer tube. During the dialysis,
EPR line intensities coming from both bound and unbound
SLSA decrease together with time (Fig. 9A). This suggests that
the amount of SLSA diffused through the membrane consists of
the SLSA released from BSA and a portion of the unbound SLSA.
Expectedly, the relative diffusion rate of SLSA increases with
temperature. At 37 1C an initial rapid release followed by a
slower release was observed. Instead, a relatively steady release
rate was observed at 25 1C. Nevertheless, the same amount of
bound SLSA (92%) is released from BSA at the end of 28 hours
both at 25 1C and 37 1C. In fact, while the total EPR intensity
was gradually decreasing, the fraction of bound SLSA (0.8) did
not change in the dialyzer tube (Fig. 9B).
We observe the bound and unbound SLSA signals together
during the dialysis. This indicates the existence of an equili-
brium between bound and unbound states.
SLSA + BSA3 SLSA–BSA complex
Fig. 7 Cw EPR spectra of constant 0.6 mM SLSA in different concentra-
tions of BSA. The concentrations of BSA are 3.00, 2.40, 1.80, 1.20, 0.90,
0.60, 0.45 and 0.30 mM in (A) and 0.24, 0.12, 0.06, 0.03 and 0.02 mM in
(B). 0.6 mM free SLSA in buffer solution was shown as a reference. The EPR
spectra are normalized to the intensity of the high field line of the unbound
SLSA. (C) Ratio of total SLSA concentration to BSA concentration is shown
by black line and the ratio of protein bound SLSA concentration to BSA
concentration is shown by red line. Protein bound SLSA ratio is obtained
from simulation of EPR spectra from (A) and (B).
Fig. 8 Sketch of SLSA binding to BSA at physiological concentrations (left)
and at lower concentrations (o0.125 mM) (right) of BSA as derived from
the cw EPR results. Spin labeled salicylic acids are shown with turquoise
salicylic acid group and yellow Tempo group. The EPR spectrum of free
SLSA is shown at top.
Paper PCCP
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
9 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
5/
07
/2
01
7 
14
:0
1:
55
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
22684 | Phys. Chem. Chem. Phys., 2015, 17, 22678--22685 This journal is© the Owner Societies 2015
Since the dialysis removes only the unbound drug from the
dialyzer tube, the equilibrium shifts to the left and promote the
SLSA release from BSA.
Kinetics of the binding process
Drug affinity for protein binding sites can be judged by Ka
(association constant), Kd (dissociation constant, 1/Ka) and DG
(binding free energy). When the drug–albumin association constant
is high, the drug releasing from albumin becomes very difficult. On
the other hand, when the drug–albumin association constant is low,
the drug loading becomes very weak and the drug is metabolized
very quickly. Therefore, a critical range between strong and weak
association is necessary for the drug transportation.
The drug–albumin association constants at different concen-
trations of albumin were calculated using EPR results from Fig. 5B
(Fig. S8 and Table S1, ESI†). The binding interaction between a
SLSA and a BSA at equilibrium is described by the following:
Ka ¼ SLSA BSA complex½ 
SLSA½   BSA½  (3)
where Ka is the association constant, [SLSA] is the concentration
of free drug, [BSA] is the concentration of free protein, and
[SLSA–BSA complex] is the concentration of the drug bound to
the protein at equilibrium. We calculated the concentrations of
[SLSA–BSA complex] and [SLSA] from their corresponding EPR
signals. [SLSA–BSA complex] corresponds to bound EPR signals
and free [SLSA] corresponds to free EPR signals. [BSA] concen-
tration is the same as the [SLSA] concentration because of the
1 : 1 ratio of initial [SLSA] : [BSA].
Drug immobilization on the protein is an entropically unfavor-
able process in an aqueous environment. Differences in the
solvation free energies of drug and protein from the drug–protein
complex provide the binding free energy of the drug with protein.
However, the formation of energetically favorable weak bindings
(electrostatic interactions, hydrophobic forces, van der Waals
interactions, and hydrogen bonds) between the drug and protein
compensates it and leads to increased Ka values. Binding free
energy (DG) of SLSA with BSA includes noncovalent interactions,
and so it can be related to the binding affinity by the following:
DG = RT lnKa (4)
where T is the experimental temperature and R is the gas constant.
Table S1 (ESI†) summarized the Ka and DG values of SLSA–BSA
complexes at different BSA concentrations (SLSA :BSA, 1 : 1).
Fig. S8 (ESI†) shows that at physiological concentrations the
Ka values are about 3.7–4.8  104 M1. Below the physiological
concentrations of albumin the Ka values decrease to about
2.0 104 M1. Above the physiological concentrations of albumin,
first the Ka values remain constant but at a high concentration for
example 1.5 mM of BSA the Ka value reaches 9.0  104 M1. These
different Ka values show that at physiological concentrations of
albumin, SLSA is loaded by albumin fairly but not so strongly
which is crucial for the drug transportation.
Conclusions
Here, we report an application of cw EPR spectroscopy to
investigate the drug binding to and release from serum albumin.
Spin labeling of a diamagnetic drug allows monitoring of the
drug directly. Therefore, we use Tempo based radicals to label
the SA drug, andmeasure the SLSA in the presence of BSA. In the
aqueous solution, the cw EPR spectroscopy clearly distinguishes
whether SLSA is bound to BSA or not due to its sensitivity to the
rotational dynamics of the SLSA.
In summary, increasing the albumin concentration, increases
the bound fraction of SLSA. Interestingly, the drug affinity of
albumin reaches the saturation point just above the physiological
concentration range (0.5–0.7 mM) of albumin. Moreover, albumin
loses its affinity for the SLSA rapidly just below the physiological
concentration range. Therefore, even a small decrease in albumin
concentration under pathological conditions may produce a large
increment in the amount of unbound drug which may lead to
toxicity.
The binding stoichiometry of SLSA to BSA was found to be
different depending on the concentration of BSA. The loading
capacity of BSA increases with increasing concentration of BSA.
At physiological concentration of BSA (0.5 mM), the maximum
loading capacity of one BSA molecule is about 7 SLSA molecules.
Whereas, for the diluted BSA concentrations (o0.125 mM)
maximum B2 SLSA can bind to one BSA molecule.
Finally, EPR data show the reversible binding of SLSA to BSA.
In the dialysis experiment, the EPR signal intensities of both
bound and unbound SLSA decrease continuously while the
ratio of bound to unbound SLSA concentrations remains con-
stant. This suggests that the bound fraction of SLSA remains
constant as long as the concentration of BSA does not change.
Fig. 9 (A) Cw EPR spectra of 0.5 mM SLSA/BSA (1 : 1) solution in a dialyzer
tube as a function of time. (B) Normalized EPR spectra of (A) to the
intensity of the high field line of the unbound SLSA. (C) The bound SLSA
release profile of BSA with time at 25 1C and 37 1C.
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